RU2621640C2 - Способы лечения рака мочевого пузыря - Google Patents

Способы лечения рака мочевого пузыря Download PDF

Info

Publication number
RU2621640C2
RU2621640C2 RU2012157805A RU2012157805A RU2621640C2 RU 2621640 C2 RU2621640 C2 RU 2621640C2 RU 2012157805 A RU2012157805 A RU 2012157805A RU 2012157805 A RU2012157805 A RU 2012157805A RU 2621640 C2 RU2621640 C2 RU 2621640C2
Authority
RU
Russia
Prior art keywords
bladder cancer
individual
composition
albumin
nanoparticles
Prior art date
Application number
RU2012157805A
Other languages
English (en)
Russian (ru)
Other versions
RU2012157805A (ru
Inventor
Нейл П. ДИСЭЙ
Патрик СООН-ШИОНГ
Original Assignee
АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45067028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2621640(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи filed Critical АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи
Publication of RU2012157805A publication Critical patent/RU2012157805A/ru
Application granted granted Critical
Publication of RU2621640C2 publication Critical patent/RU2621640C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heat Treatment Of Steel (AREA)
RU2012157805A 2010-06-02 2011-05-20 Способы лечения рака мочевого пузыря RU2621640C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39680010P 2010-06-02 2010-06-02
US61/396,800 2010-06-02
US201161449513P 2011-03-04 2011-03-04
US61/449,513 2011-03-04
PCT/US2011/037449 WO2011153009A1 (en) 2010-06-02 2011-05-20 Methods of treating bladder cancer

Publications (2)

Publication Number Publication Date
RU2012157805A RU2012157805A (ru) 2014-07-20
RU2621640C2 true RU2621640C2 (ru) 2017-06-06

Family

ID=45067028

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012157805A RU2621640C2 (ru) 2010-06-02 2011-05-20 Способы лечения рака мочевого пузыря

Country Status (20)

Country Link
US (2) US20130266659A1 (enExample)
EP (1) EP2575803B1 (enExample)
JP (1) JP2013527232A (enExample)
KR (1) KR20130109025A (enExample)
CN (1) CN103221042B (enExample)
AU (1) AU2011261684B2 (enExample)
BR (1) BR112012030699A2 (enExample)
CA (1) CA2801314A1 (enExample)
CO (1) CO6620019A2 (enExample)
CR (1) CR20120619A (enExample)
ES (1) ES2639038T3 (enExample)
MX (1) MX343671B (enExample)
MY (1) MY188911A (enExample)
NI (1) NI201200175A (enExample)
NZ (2) NZ708506A (enExample)
PH (2) PH12012502378A1 (enExample)
RU (1) RU2621640C2 (enExample)
SG (1) SG186109A1 (enExample)
WO (1) WO2011153009A1 (enExample)
ZA (1) ZA201208815B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
ES2678448T3 (es) 2005-02-18 2018-08-10 Abraxis Bioscience, Llc Combinaciones y modos de administración de agentes terapéuticos y terapia combinada
TWI417114B (zh) 2005-08-31 2013-12-01 Abraxis Bioscience Llc 具有增強穩定性之弱水溶性藥物之組合物及其製備方法
CA2672618C (en) 2006-12-14 2021-03-02 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
KR20090118999A (ko) * 2007-03-07 2009-11-18 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
DK2155188T3 (da) 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
ES2580135T3 (es) 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ628423A (en) 2010-03-29 2016-03-31 Abraxis Bioscience Llc Methods of treating cancer
WO2011143656A2 (en) 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
KR101850566B1 (ko) * 2010-06-07 2018-04-19 아브락시스 바이오사이언스, 엘엘씨 증식성 질환의 치료를 위한 조합 치료 방법
CA3063641A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
DK2790675T3 (da) 2011-12-14 2019-09-09 Abraxis Bioscience Llc Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler
DK177379B1 (en) * 2012-03-29 2013-02-25 Entomopharm Aps Insect-based model to study the effect and integrity of nanoparticles on blood-brain barrier function
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140199404A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
NZ630392A (en) 2013-03-12 2016-10-28 Abraxis Bioscience Llc Methods of treating lung cancer
NZ630367A (en) * 2013-03-13 2017-02-24 Abraxis Bioscience Llc Methods of treatment of pediatric solid tumor
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
BR112016014410A2 (pt) 2013-12-20 2018-02-20 The Broad Institute Inc. terapia de combinação com vacina de neoantígeno
WO2015018380A2 (en) * 2014-07-03 2015-02-12 Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. Therapeutic nanoparticles and the preparation methods thereof
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
HK1252267A1 (zh) 2015-05-20 2019-05-24 The Broad Institute Inc. 共有的新抗原
CA3026452C (en) 2015-06-04 2023-03-21 Crititech, Inc. Nozzle assembly and methods for use
HUE070408T2 (hu) 2015-06-29 2025-06-28 Abraxis Bioscience Llc Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra
EP3313381A4 (en) * 2015-06-29 2019-02-27 Abraxis BioScience, LLC BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
US20170027941A1 (en) * 2015-07-31 2017-02-02 Pharmacyclics Llc Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof
CA3018989A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
KR20220123317A (ko) * 2016-05-06 2022-09-06 타리스 바이오메디컬 엘엘씨 하부 요로 요로상피암을 치료하는 방법
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3058807A1 (en) 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Protein antigens and uses thereof
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
KR20210118468A (ko) 2017-06-14 2021-09-30 크리티테크, 인크. 폐 장애의 치료 방법
CA3071014A1 (en) 2017-07-25 2019-01-31 Taris Biomedical Llc Methods of treating tumor metastasis
RU2020110399A (ru) 2017-10-03 2021-11-09 Крититек, Инк. Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
JP2021502347A (ja) 2017-11-08 2021-01-28 タリス バイオメディカル エルエルシー ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
AU2019205916A1 (en) * 2018-01-05 2020-07-02 Crititech, Inc. Treatment of bladder cancer by local administration of taxane particles
WO2019183146A1 (en) 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
JP2022553426A (ja) 2019-10-28 2022-12-22 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物
WO2024102620A2 (en) * 2022-11-09 2024-05-16 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063110A1 (en) * 1998-05-30 1999-12-09 Imperial College Innovations Limited Diagnosis and treatment of cancer
US6544544B2 (en) * 1993-07-19 2003-04-08 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
WO2008060651A2 (en) * 2006-03-31 2008-05-22 Abraxis Bioscience, Inc. Sparc and methods of use thereof
RU2361615C2 (ru) * 2002-12-09 2009-07-20 Абраксис Байосайенс, Ллс. Композиции и способы доставки фармакологических агентов

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
JP5368093B2 (ja) 2005-08-31 2013-12-18 アブラクシス バイオサイエンス， エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
JP5641927B2 (ja) * 2007-04-13 2014-12-17 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ及びその使用方法
EP3326630A3 (en) 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
BRPI0922823A2 (pt) * 2008-12-11 2015-08-18 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
NZ598588A (en) * 2009-08-25 2014-05-30 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544544B2 (en) * 1993-07-19 2003-04-08 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
WO1999063110A1 (en) * 1998-05-30 1999-12-09 Imperial College Innovations Limited Diagnosis and treatment of cancer
RU2361615C2 (ru) * 2002-12-09 2009-07-20 Абраксис Байосайенс, Ллс. Композиции и способы доставки фармакологических агентов
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
WO2008060651A2 (en) * 2006-03-31 2008-05-22 Abraxis Bioscience, Inc. Sparc and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAHA HUSSAIN et al. Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer, Journal of Clinical Oncology, Vol 19, No 9 (May 1), 2001: pp 2527-2533. *
ZANCONG SHEN et al. Intravesical Treatments of Bladder Cancer: Review, Pharmaceutical Research, Vol. 25, No. 7, July 2008, р. 1502-06. LAUDANO MA et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy, Urology. 2010 Jan;75(1):134-7. GURU SONPAVDE et al. Novel agents for advanced bladder cancer, Ther Adv Med Oncol (2009) 1(1) 37-50, р. 37-40. *

Also Published As

Publication number Publication date
CR20120619A (es) 2014-03-21
CO6620019A2 (es) 2013-02-15
MY188911A (en) 2022-01-13
CA2801314A1 (en) 2011-12-08
CN103221042B (zh) 2016-02-10
MX343671B (es) 2016-11-16
ZA201208815B (en) 2014-01-29
SG186109A1 (en) 2013-01-30
US20130266659A1 (en) 2013-10-10
AU2011261684A1 (en) 2013-01-10
CN103221042A (zh) 2013-07-24
ES2639038T3 (es) 2017-10-25
PH12012502378A1 (en) 2013-02-11
PH12016502066A1 (en) 2019-02-04
MX2012013909A (es) 2013-02-21
NZ604029A (en) 2015-07-31
EP2575803B1 (en) 2017-07-26
WO2011153009A1 (en) 2011-12-08
NZ708506A (en) 2016-08-26
KR20130109025A (ko) 2013-10-07
EP2575803A4 (en) 2014-01-01
BR112012030699A2 (pt) 2016-09-13
RU2012157805A (ru) 2014-07-20
US20140056986A1 (en) 2014-02-27
NI201200175A (es) 2013-05-13
JP2013527232A (ja) 2013-06-27
AU2011261684B2 (en) 2016-09-15
EP2575803A1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
RU2621640C2 (ru) Способы лечения рака мочевого пузыря
AU2018200347B2 (en) Methods of treatment of pancreatic cancer
US9370494B2 (en) Methods for treating hepatocellular carcinoma
JP6342918B2 (ja) 膵臓がんの処置方法
CN103169729A (zh) 治疗剂的组合和给予方式以及联合治疗
CA3039582A1 (en) Methods of treating biliary tract cancer
HK1183816B (en) Methods of treating bladder cancer
HK1183816A (en) Methods of treating bladder cancer
HK40009403A (en) Methods of treating pancreatic cancer
HK1181665B (en) Methods of treatment of hepatocellular carcinoma